



Altru NYC Oncology Conference

May 8-9, 2018 | New York, NY




CONFERENCE SERIES SPONSORS





May 8 Agenda

8:00 AM	BREAKFAST
9:00 AM	Jack Hidary - Application of AI to Cancer (Google Fellow, Clinton Initiative)
9:30 AM	Dr. Sujuan Ba - NCFR / Update on International GBM-Agile Adaptive Trial
10:00 AM	Corporate Presentation - SageMedic
10:30 AM	Corporate Presentation - Vitanova
11:00 AM	Corporate Presentation - OTraces
11:30 AM	Corporate Presentation - Hoopika
12:00 PM	Corporate Presentation - RXI
12:30 PM	Corporate Presentation - Trethera
1:00 PM	LUNCH TALK - Alfred Slanetz (Former Bluebird CEO) Update on T-Cell Therapies
1:30 PM	Corporate Presentation - TargaGenix
2:00 PM	Corporate Presentation - Soligenix
2:30 PM	Corporate Presentation - CytRx
3:00 PM	Corporate Presentation - Mersana
3:30 PM	Corporate Presentation - 3DBiopsy
4:00 PM	Corporate Presentation - Aphios
4:30 PM	Wilson Sonsini - Discussion of IP Protection in Life Sciences
5:00 PM	Corporate Presentation - NED Biosystems
5:30 PM	Corporate Presentation - RNA Diagnostics
6:00 PM	Isaac Blech - Investing in Early Stage Biotech
6:30 PM	Reception




SPEAKER BIOGRAPHIES



Issac Blech


Mr. Blech is a renowned biotechnology entrepreneur and investor, who, over the past 35 years, has founded and served on the board of companies which have produced major advances in a broad array of diseases. The companies he established include: (1) Celgene Corporation, the world's leader in cancer and hematology with a current market value in excess of \$80 billion, (2) ICOS Corporation, developer of the drug Cialis that was later purchased by Eli Lilly, (3) Nova Pharmaceutical Corporation, developer of a new treatment for brain cancer, Gliadel, later acquired by Johnson and Johnson, (4) Pathogenesis Corporation, developer of the leading drug for cystic fibrosis that was eventually bought by Chiron, and (5) Genetics Systems Corporation, developer of the first rapid accurate diagnostic for

chlamydia and the first accurate test to safe guard the world's blood supply from the AIDS virus, before being purchased by Bristol Myers. Mr. Blech's current roles include Director of Cerecor, Inc., a CNS company, Director of ContraFect Corporation, an infectious disease company, Vice Chairman of Edge Therapeutics, Inc., a company that treats life-threatening neurological conditions and Vice Chairman of InspireMD, a stent company. He is Vice Chairman of Centrexion Corporation, a private company which is developing new modalities of pain control, Vice Chairman of X4 Pharmaceuticals, a private cancer immunology company, Vice Chairman of Sapience Therapeutics, an private oncology company and Vice Chairman of Aridis Pharmaceuticals, a private company with a product to treat pneumonia. He also serves as Vice Chairman of WaveGuide Corporation, a private company developing the world's smallest NMR machine, and Vice Chairman of Alveo, a private company developing a hand held diagnostic device to replace PCR. He is also Vice Chairman of X-VAX Technology, Inc., a private vaccine company whose initial product is a preventative vaccine for Herpes 1 and Herpes 2. He is also Vice Chairman of SpendSmart Networks, Inc., an electronic rewards company.



May 9 Agenda

8:00 AM	BREAKFAST
9:00 AM	Dennis Purcell - Developments in Oncology Venture Capital
9:30 AM	Bryan Leland-Jones - Translational Medicine and Improving the Pipeline Process
10:00 AM	Corporate Presentation - SciTech Development LLC
10:30 AM	Corporate Presentation - Rad Immune
11:00 AM	Corporate Presentation - Tosk
11:30 AM	Corporate Presentation - Alpha Cancer
12:00 PM	Corporate Presentation - VolitionRx
12:30 PM	Corporate Presentation - CEL-SCI
1:00 PM	LUNCH—Life Science Venture Capital Panel
1:30 PM	Lili Gil Valletta - How Big Data and AI Tools Can Uncover Barriers Throughout The Patient Journey"
2:00 PM	Corporate Presentation - 20/20 Gene Systems
2:30 PM	Corporate Presentation - TapImmune
3:00 PM	Corporate Presentation - International Cancer Impact Fund / AIM-HI -
3:30 PM	Corporate Presentation - Aurroa Biopharma
4:00 PM	Corporate Presentation - Immunicom
4:30 PM	Corporate Presentation - Geneius
5:00 PM	Closing Keynote—Isaac Blech



SPEAKER BIOGRAPHIES




Jack Hidary

Jack focuses on AI and the application of AI to science at Alphabet/Google X. After doing research in neuroscience and AI at the NIH, Jack followed his fascination with technology and established EarthWeb, a company dedicated to the needs of tech professionals. Jack co-founded the company with his brother Murray Hidary and friend Nova Spivack. Jack led the company from its inception through three rounds of investment and then its IPO on NASDAQ. Under Jack's leadership, EarthWeb acquired Dice.com, a website that connects users with jobs, and other sites dedicated to the needs of IT professionals.

As Chairman and CEO of the public company, Jack continued to grow the company and engage with shareholders, customers and analysts. After running the public company for more than three years, Jack handed off to a new CEO. After handing off management of the company, Jack became active in public service. He got engaged in helping small businesses grow and championing new models of education. Jack has served as a partner at the Partnership for NYC, a trustee of the Citizens Budget Commission and a member of the steering committee of ABNY. He has been a board member of Trickle Up which helps thousands of entrepreneurs start small businesses each year. Jack is a frequent commentator on Bloomberg TV, Fox Business and other channels. Jack launched the Hidary Foundation, is a Founding Member of the Clinton Global Initiative, and ran for New York City Mayor.

Jack has been recognized for his leadership by organizations such as the World Economic Forum. Jack studied neuroscience at Columbia and then received the Stanley Fellowship in Clinical Neuroscience at NIH where he worked on functional brain imaging and neural networks



SPEAKER BIOGRAPHIES




Denis Purcell

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.



SPEAKER BIOGRAPHIES




Dr. Sujuan Ba

Dr. Ba is the President and Chief Operating Officer of the National Foundation for Cancer Research (NFCR) and is recognized as one of the “Top 300 Women Leaders in Global Health” by the Global Health Programme at the Graduate Institute of International and Development Studies. Dr. Ba oversees NFCR’s strategic directions for fundraising, financial planning, scientific direction and partnership development. Dr. Ba leads the establishment of NFCR’s annual [Szent-Györgyi Prize for Progress in Cancer Research](#), an international prize in recognition of outstanding scientific achievement in the war against cancer. She has served continuously for the past 12 years as co-chair of the Prize Selection Committee which consists of leaders in academic and pharmaceutical sectors. Dr. Ba also founded the [Asian Fund for Cancer Research](#) (AFCR), a non-profit organization headquartered in Hong Kong. As CEO of AFCR, Dr. Ba oversees the fund’s collaborative research initiatives and public prevention programs in Hong Kong, Greater China, and throughout Asia.

Dr. Ba currently serves on the executive committee and Co-Chair of the Patient Focused Research and Advocacy Committee of the GBM-AGILE (Adaptive Global Innovative Learning Environment), a global trial to improve the survival of GBM patients with a global force of over 150 neurosurgeons, neuro-oncologists, pathologists, imagers, basic and clinical neuro scientists, from academic, industry, and government. She is a member of the Scientific Advisory Board of Medelis, Inc., an oncology CRO located in Fountain Hills, AZ. She also serves on the International Consulting Committee of the China National Research Center for Translational Medicine in Shanghai. Dr. Ba is a member of BayHelix, an invitation-only organization of leaders of Chinese origin in the global life sciences and healthcare community based in San Francisco with regional offices in Shanghai and Beijing.

Dr. Ba served on the Organizing Committee for the 2015 Personalized Medicine Conference, a cross-industry, cross-disciplinary panel made up of providers, payers, educators, researchers, and government agency representatives—all committed to personalized medicine. She served as a Past President (2010-2011) Board of Directors (2006-2013) and is currently a member of the Board of Advisors of the Chinese Biopharmaceutical Association—USA (Rockville, MD). In 2011, she was invited as one of a few business leaders to join Maryland Governor Martin O’Malley’s Trade Mission to Asia and visited China, Korea, and Vietnam with Governor O’Malley. She also served on the Membership Committee of the International Union against Cancer (Geneva). Prior to joining NFCR, Dr. Ba was the Director of Chiral Chemistry and Fine Chemical Consulting Services at Technology Catalysts International (TCI) where she conducted market research, business evaluation, and competitive intelligence for an international clientele of major chemical and pharmaceutical companies. From 1991-1997, she was a Principal Research Chemist and then Project Manager of Technology Development and Research Planning at Arco Chemical Company (ARCO). Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.



SPEAKER BIOGRAPHIES



Lili Gil Valletta


Lili came to the U.S. at the age of 17 with a suitcase, leaving her family behind in Colombia, without speaking English but determined to achieve the American Dream.

Today, Lili is a recognized cultural intelligence™ expert, World Economic Forum Young Global Leader and an award-winning entrepreneur. After a successful corporate career including a 10-year tenure at Johnson & Johnson, where she pioneered various diversity and cultural marketing strategies, Lili co-founded [CIEN+](#) and [CulturIntel](#). Her firm, based in New York City with offices in Minneapolis and Colombia, offers big-data analytics, business consulting and marketing strategies to help leaders and Fortune 500's successfully turn cultural trends and diversity into innovation and profits.

Her methods of Cultural Intelligence™ and ability to use big data, machine learning and AI tools to mine global insights from open-sourced digital discussions, have been featured at numerous global conferences, news outlets and universities like Harvard University, Princeton University, among others.

She is a [regular TV commentator](#) seen on Fox News, Fox Business and CNN en Español, and has been featured by [Forbes](#), [CNN Money](#), [The Huffington Post](#), The NY Daily News, [MM&M](#), among others. She is the recipient of many awards including 2017 Top 50 Health Influencer and is also an advocate to minority business contributing to initiatives at The United Nations, [The World Economic Forum](#), [The White House](#) and around the world. Lili serves as a board member of the [Harvard Women's Leadership Board](#), National [Board of Directors of the YMCA USA](#), mentor to the Stanford Latino Entrepreneur Leaders Program. In 2017 she was appointed by New York City Mayor Bill de Blasio as part of the [NYCx Technology Leadership Council](#) and by Governor Cuomo to join the [New York State Council on Women and Girls](#).

She holds a degree in Business Administration from Southwestern Adventist University, completed foreign studies in Commerce at Deakin University in Melbourne, Australia, M.B.A. from the University of Colorado and an executive degree from the Harvard Kennedy School in Global Leadership and Public Policy. She lives in New York City with her husband, entrepreneur and former NFL player Chris Valletta and her two sons.



COMPANY DESCRIPTIONS




Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in oncology and autoimmune disease indications. The company's drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immunoncology properties. ACT has exclusive worldwide rights to the targeted delivery platform Alpha Fetoprotein with over \$100 million spent on the development of the in-licensed technology. Clinical studies of AFP have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.



Aphios, is researching and developing anticancer therapeutics and supportive care drugs from medicinal plants and marine organisms based on the company's enabling technology platforms of drug discovery, manufacturing and delivery. Aphios' goal is to develop therapies to treat cancer as a chronic rather than acute disease, provide the less toxic and mostly plant-based natural drugs such as nanoformulations of Taxol® and Taxotere® that can be used in an acute setting until long-term preventative solutions can be developed, and to provide supportive care for cancer patients undergoing acute treatment.



Aurora Biopharma, Inc., a biopharmaceutical company, develops therapies for solid tumor cancers. The company develops chimeric antigen receptor (CAR) T cells, a therapy in which cancer patients blood is withdrawn and their T cell is extracted from their white blood cells, genetically edited to express a CAR specific to that type of cancer cell, and re-infused back to the patient to target and kill cancer cells. Its platform targets main and co-stimulatory solid tumor associated antigens present on a range of solid tumor cancers, starting with brain tumors, sarcomas, and breast cancers.



COMPANY DESCRIPTIONS




CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma. CEL-SCI has received patents for Multikine from the US, Europe, China and Japan.



Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to be well tolerated, tumor localizing, and overcomes platinum drug resistance in pharmacological in vitro human cancer models. These attributes have high value in multiple indications that do not respond to platinum or biologicals, such as immunotherapies.



CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ tunable linker technologies to provide targeted delivery, release and accumulation of the cytotoxic drug payloads at the tumor site. CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.



COMPANY DESCRIPTIONS




Geneius is a private biopharmaceutical company run by the Former CEO of Bluebird Bio focused on the discovery and clinical development of adoptive T cell therapy products that address the treatment of cancer and infections. The company has created a good manufacturing process, or GMP, for the production of T cells from peripheral blood for infusion into the patient, allowing for manufacturing at a price of 1/10th that of traditional CAR-T. Geneius' targeted DiversiTy™ platform is a novel ex vivo approach that re-educates T cells to become responsive to multiple, previously overlooked tumor antigens. Geneius' lead product candidate, GNS-TEBV-001, is currently in preclinical testing for EBV+, NHL, gastric and nasopharyngeal cancers. Geneius also has two additional products, GNS-TGBM-002 and GNS-TPC-003, in preclinical testing for glioblastoma and pancreatic cancer, respectively.



Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. The company's proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa's vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.



Immixon Biopharma, Inc. develops novel therapies for cancer patients. The company's products include Imx-110 which is a nanoparticle delivery vehicle, co-loaded with small doses of cytotoxin and a potent agent that has shown synergy with multiple cytotoxic agents, such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies, and radiation; and Imx-111 which is a targeted form of Imx-110. Further, the company develops multi-component drug candidates. Immixon Biopharma, Inc. primarily caters to chemotherapy and immunotherapy-resistant patients.



COMPANY DESCRIPTIONS




Immunicom has leveraged the latest, cutting-edge clinical research in immune regulatory pathways and their role in cancer and autoimmune disease to develop a revolutionary immunotherapy platform (Immunopheresis™) for treating cancer and other terminal diseases through a BLOOD FILTERING DEVICE. We filter a patient's blood of "blocking proteins" released by cancer cells that suppress the immune system. Once these proteins are removed, the immune system naturally attacks the tumor and cancer. Immunicom is led by Amif Jafri, the Former Head of R&D of Cardinal Health. The company first target is STNFr.



ImmunoCellular is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.



Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary antibody drug conjugate (ADC) platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. Mersana's second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.



COMPANY DESCRIPTIONS




NED Biosystems is a biotechnology company developing an advanced, fast-to-market oral combination therapy to treat multiple cancer indications. Our lead therapeutic candidate, NED-170, simultaneously targets five key processes that drive survival and growth of all advanced cancer. This multi-pronged approach has proven effective in some of humanity's most intractable diseases and helps prevent the "breakthrough" (limited durability of effect) seen with many more narrowly targeted cancer treatment approaches, and at the same time prioritizes high patient quality of life.



OTRaces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTRaces has solved the problem of deciphering biomarker activity within the TME, which has come to be recognized and accepted in science as a vast storehouse of diagnostic content exceeding the tumor itself. It is the only blood test known to determine tumor status and progression.



RadImmune Therapeutics is a private biotechnology company about to enter the clinic with its first product. Radimmune is pioneering innovative therapies via its proprietary antibody drug conjugation (ADC) and antibody radio-conjugation (ARC) platform for melanoma, pancreatic and additional cancer types. Radimmune currently has three pre-clinical programs in oncology and expects to launch a Phase 1 trial in melanoma (cutaneous, acral and uveal) by year-end 2018 and a Phase 1 trial in pancreatic cancer in 2019. RadImmune is led by an experienced management team that has both taken companies public and led successful oncology clinical development programs.



COMPANY DESCRIPTIONS




A major unmet need in oncology today is the inability to assess quickly which patients are responding to medications, and which patients are not. This leads to delays in effective care, over-treatment, unnecessary toxicities and over \$60 billion in waste every year. Rna Diagnostics has developed the RNA Disruption Assay (RDA) to address this major unmet need. RDA tells oncologists, within the first 2-3 weeks of treatment, if a patient's tumor is responding to the drugs prescribed or not. RDA will enable a revolution in oncology care: response guided cancer treatment. If a patient is not responding, the doctor can move on to the next best alternative, surgery, radiation, or different drugs. This approach will improve survival, reduce unnecessary toxicity, and save healthcare systems money.



RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.



SageMedic is creating a 3D micro-tumor assay to help physicians determine the best cancer treatment for their patient. To do so, we take a live tumor biopsy, create hundreds of 3D micro-tumors, expose them to a wide range of anti-cancer drugs (e.g. chemotherapy or targeted therapy), and measure the response to identify the most effective treatment that will be communicated with the treating oncologist.



COMPANY DESCRIPTIONS



Enabling proven cancer drugs

SciTech Development, LLC is a clinical stage, biopharmaceutical company that converted fenretinide, an underperforming yet proven anticancer agent, into a fully functional intravenous (IV) drug for the treatment of numerous cancers. SCI's clinical lead compound, ST-001, is a short-development track anticancer agent delivered in a novel nanoparticle-based system. Fenretinide has shown clinical, targeted cancer destroying activity and, when combined with SCI's new, patented, nanoparticle delivery system, promises to save many lives. Initially, it was clinically tested and shown to be safe in a breast cancer prevention trial of more than 3,000 women. It later evolved into a cancer therapeutic and was shown to be effective in treating many other cancers. Development of fenretinide was hindered by low active drug concentrations and by the side effects associated with poorly designed IV delivery systems. ST-001 overcomes those problems by delivering greater concentrations safely at the required dose levels. It will initially target T-cell lymphoma and small cell lung cancer followed by broader market opportunities that include leukemia, breast, ovarian, lung, pancreatic, prostate, renal cell and other cancers previously shown to respond to fenretinide.




SOLIGENIX

Soligenix, Inc., a late-stage, public biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.



TAPIMMUNE

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. The company's peptide-or nucleic acid-based immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. It also focuses on developing PolyStart, a DNA expression technology, which is in pre-clinical stage to enhance the ability of the cellular immune system to recognize and destroy diseased cells.



COMPANY DESCRIPTIONS




TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company's lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate "stemness" gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.



Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call Companion™ drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.



Trethera is a clinical-stage biopharmaceutical company developing cancer treatments for orphan blood cancers with high unmet needs. The Company is led by an experienced drug development team and was founded by highly recognized UCLA faculty successful in bringing medical products to market. Focusing on the pathways controlling cancer nucleotide metabolism led to the development of TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK) that is targeted to enter a Phase 1 clinical study in H1 2018.



COMPANY DESCRIPTIONS




20/20 GeneSystems ("20/20") is focused on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine learning and data analytics, new tests are being released which substantially improve the accuracy of biomarker blood tests for the early detection of cancers. This unique approach, being pioneered by 20/20, results in affordable, highly accurate cancer blood tests.



Vitanova Biomedical Incorporated (VNB) is a private San Antonio, Texas-based early-stage biotechnology company focusing on the development and implementation of proprietary intellectual property that has proven successful in killing cancer in vitro (in a petri dish). Currently, we are conducting pre-clinical trials utilizing our proprietary light-activated acidosis therapy to treat and kill multiple types of aggressive cancer cells, and have secured our CRO (Clinical Research Organization) partner (Cancer Insight, San Antonio, TX) to conduct our Phase I through Phase III clinical testing.




Volition is a multi-national, publically-traded, life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's initial Nu. Q™ products are focusing on colorectal cancer. Colorectal cancer is ranked second among all newly diagnosed cancers.



REGISTERED INVESTORS—MAY 2018

ADDF	Kingdon Holdings
AIM-HI Cancer Fund	Landmark Angels
Aleph Capital	Luader FO
Aisling Capital	Leaf Capital
Arix Biosciences	Leukemia and Lymphoma Society VC Fund
ATEM Capital	Lincoln Park Capital
Beechwood FO	Lionchase
Biosense Global	Lopes de Souza (SFO)
Boston Millenia Partners	LS Works
Broms Asset Management (Todd/Nelson Broms)	Maxim Merchant Banking & Private Equity
Camden Partners	M Ventures (Merck Ventures)
China Grand	MedPro Investors
Cynergy Brookline Healthcare Fund	Mid-Atlantic Angels
Dabar Investment Associates	Momentum Biotech
Dandrew Partners (FO)	Monarch Holdings
Easton Capital	Murdock Capital / Murdock Opportunity Fund
Ellington Healthcare Partners / NSIP	NJ Angels
Elser & Co.	Olympus Corporation Venture Capital
Emerging Star Capital	OPKO
Excelyrate (Mass Inn Labs VC Fund)	OneMed Market
Fortress Biotech	Park Avenue Capital
4Bio Capital	Patriot Strategies
Gonzalez Family Office	Puck Ventures (FO)
Good Health Capital	Remiges Ventures
Gore Range Capital	Sandbox (BC/BS VC Fund)
Gorlin Companies SFO	Sixiang Holdings (SFO)
GSK Ventures	Syzygy Therapeutics Management
Harvard FO Club	3VS1
Healthbox (Intermountain Health VC)	Touchdown VC
HIG Bio	Varana Capital
International Cancer Impact Fund	Vista Capital
Isaac Blech	Wellington Management
JD Capital	Willet (Bloomberg FO)
Keiretsu Forum	YuanMing Capital



Altru NYC Oncology Conference

May 8-9, 2018 | New York, NY

RECENT CONFERENCES



10th Annual OneMedForum @ JPM

January 9-11, 2017

Kensington Park Hotel, San Francisco



NYC Annual Life Science Conference

November 9-10, 2017


The Grace Building, New York



Klosters Oncology and Women's Health Conferences @ World Economic Forum

January 23-26, 2018

Klosters & Davos, Switzerland



Altru NYC Oncology Conference

May 8-9, 2018 | New York, NY

FUTURE CONFERENCES



NYC Fall Oncology Investor Conference

Oct 30-31, 2018

Rockefeller Center, New York



Oncology Conference @ JPM

January 9, 2019

Kensington Park Hotel, San Francisco



NYC Spring Oncology Investor Conference

May 10-11, 2019

Rockefeller Center, New York



Boston Oncology Investor Conference

September 4, 2019

Boston

